ESTA vs HCA: fair value comparison
Establishment Labs Holdings Inc. and HCA Healthcare, Inc. · Updated 2026-10-19
ESTA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ESTA currently ranks higher by quality score.
| ESTA | HCA | |
|---|---|---|
| Verdict | No estimate yet | Fairly valued |
| Last price | $59.18 | $451.09 |
| 12-month range | $47.80–$95.65 | $361.32–$545.13 |
| Rank by discount to fair value | — | #56 of 108 Healthcare |
| Rank by quality score | #156 of 301 Healthcare | #157 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | High | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: ESTA fair value analysis · HCA fair value analysis